GO
Loading...

Celgene Corp

More

  • Market Insider/Thursday Look Ahead Wednesday, 7 May 2008 | 7:48 PM ET

    Retailers' April sales reports could shape early market action Thursday and provide a window on just how the consumer is faring.

  • Health Care Stocks with Healthy Outlooks Thursday, 24 Apr 2008 | 1:10 PM ET

    What's the best sector for improving your stock portfolio near-term?  Jeff Krumpleman of Fifth Third Asset Management thinks it's health care, and he has some specific selections that back him up.

  • Clank of America Monday, 21 Apr 2008 | 6:17 PM ET

    The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"

  • Happy Birthday CNBC - Markets Then and Now Thursday, 17 Apr 2008 | 9:24 AM ET

    Today, April 17, is CNBC's 19th birthday. Just look at how things have appreciated since then.

  • Month and Quarter End Winners and Losers Monday, 31 Mar 2008 | 4:53 PM ET

    Thank goodness Q1 is over!  Here's a summary of month-end and Q1 stats for stocks, commodities and currencies...

  • Lightning Round: Celgene, Apple, Chevron and More Tuesday, 25 Mar 2008 | 7:09 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • The Return of Big Pharma Friday, 14 Mar 2008 | 6:44 PM ET

    This could be the sector to own by next fall's presidential election.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Stocks Rebound; Oil Hits $104 Wednesday, 5 Mar 2008 | 9:18 PM ET

    The Dow snaps a losing streak as oil hits another all-time high. Get the news behind the headlines in the Word on the Street.

  • A Biotech Worth Buying? Wednesday, 6 Feb 2008 | 6:58 PM ET

    In Wednesday’s Web Extra, Pete Najarian reveals how he’s playing biotech. Could these stocks be just what the doctor ordered?

  • What the Pros Like: Where to Invest In This Market Wednesday, 6 Feb 2008 | 4:10 PM ET

    Stocks are having another up and down day.  So CNBC asked the experts where they would put their money in this kind of market.

  • Recession Nerves = Great Buying Opportunity Wednesday, 6 Feb 2008 | 3:01 PM ET

    David Spika, WHG Funds vice president, isn't afraid to use the "R" word -- but he's no bear.  He thinks the recession talk is overdone, making now a great time to buy stocks. He and Jeff Krumpelman of Fifth Third Asset Management offered CNBC their top picks.

  • Am I Nuts? Tuesday, 22 Jan 2008 | 7:59 PM ET

    Dr. Cramer's in. For this segment, he listens to investors lament about their portfolio problems.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • Healthy Returns? Friday, 4 Jan 2008 | 6:51 PM ET

    What's the trade heading into next week's JPMorgan Healthcare Conference?

  • Mad Mail: What's the Best Way to Play Spec Stocks? Friday, 4 Jan 2008 | 11:21 AM ET

    Plus, Cramer the Scary Monster and lost faith in Celgene.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • On the Line: Celgene COO Bob Hugin Wednesday, 12 Dec 2007 | 10:44 AM ET

    Has Cramer's favorite biotech stock lost its swagger? Not so fast.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Lightning Round: Cynosure, EMC, Pfizer and More Tuesday, 4 Dec 2007 | 10:48 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Lightning Round: Akamai, Elan and Under Armour Wednesday, 28 Nov 2007 | 11:13 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.